Latest Insider Transactions at Scholar Rock Holding Corp (SRRK)
This section provides a real-time view of insider transactions for Scholar Rock Holding Corp (SRRK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Scholar Rock Holding Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Scholar Rock Holding Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 10
2024
|
Invus Public Equities, L.P. |
SELL
Open market or private sale
|
Direct |
1,600,000
-14.75%
|
$65,600,000
$41.65 P/Share
|
|
Nov 25
2024
|
Invus Public Equities, L.P. |
SELL
Open market or private sale
|
Direct |
409,433
-0.74%
|
$15,967,887
$39.34 P/Share
|
|
Nov 25
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
6,375
-2.06%
|
$248,625
$39.49 P/Share
|
|
Nov 25
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,375
+7.45%
|
$51,000
$8.59 P/Share
|
|
Nov 22
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,145
-2.86%
|
$64,350
$30.01 P/Share
|
|
Nov 22
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,145
+2.78%
|
$17,160
$8.59 P/Share
|
|
Nov 12
2024
|
Michael Gilman |
BUY
Bona fide gift
|
Direct |
37,459
+42.37%
|
-
|
|
Nov 12
2024
|
Michael Gilman |
SELL
Bona fide gift
|
Indirect |
37,459
-100.0%
|
-
|
|
Nov 11
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,105
-2.81%
|
$63,150
$30.0 P/Share
|
|
Nov 11
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,105
+2.73%
|
$16,840
$8.59 P/Share
|
|
Oct 08
2024
|
Edward H Myles COO & CFO |
SELL
Open market or private sale
|
Direct |
37,187
-18.76%
|
$1,264,358
$34.9 P/Share
|
|
Oct 08
2024
|
Edward H Myles COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
37,187
+15.79%
|
$371,870
$10.0 P/Share
|
|
Oct 07
2024
|
Edward H Myles COO & CFO |
SELL
Open market or private sale
|
Direct |
206,240
-18.28%
|
$5,568,480
$27.19 P/Share
|
|
Oct 07
2024
|
Edward H Myles COO & CFO |
SELL
Exercise of conversion of derivative security
|
Direct |
206,240
-35.96%
|
$2,681,120
$13.83 P/Share
|
|
Oct 07
2024
|
Tracey Sacco CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
30,000
-19.6%
|
$750,000
$25.91 P/Share
|
|
Oct 07
2024
|
Tracey Sacco CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+27.45%
|
$300,000
$10.0 P/Share
|
|
Oct 07
2024
|
Srinivas Akkaraju |
SELL
Open market or private sale
|
Indirect |
1,175,713
-6.11%
|
$35,271,390
$30.0 P/Share
|
|
Oct 07
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
109,375
-24.77%
|
$2,953,125
$27.29 P/Share
|
|
Oct 07
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
109,375
+37.51%
|
$875,000
$8.59 P/Share
|
|
Sep 16
2024
|
Mo Qatanani CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,936
-1.34%
|
$15,488
$8.58 P/Share
|
|
Aug 16
2024
|
Caryn Parlavecchio CHRO |
SELL
Open market or private sale
|
Direct |
1,451
-0.95%
|
$13,059
$9.33 P/Share
|
|
Jun 27
2024
|
Kristina Burow |
BUY
Grant, award, or other acquisition
|
Direct |
13,500
+41.75%
|
-
|
|
Jun 27
2024
|
Katie Peng |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+12.56%
|
-
|
|
Jun 27
2024
|
Joshua Reed |
BUY
Grant, award, or other acquisition
|
Direct |
13,500
+50.0%
|
-
|
|
Jun 27
2024
|
Akshay Vaishnaw |
BUY
Grant, award, or other acquisition
|
Direct |
13,500
+37.03%
|
-
|
|
Jun 27
2024
|
Jeffrey S. Flier |
BUY
Grant, award, or other acquisition
|
Direct |
13,500
+37.49%
|
-
|
|
Jun 27
2024
|
Michael Gilman |
BUY
Grant, award, or other acquisition
|
Direct |
13,500
+50.0%
|
-
|
|
Jun 27
2024
|
Richard Brudnick |
BUY
Grant, award, or other acquisition
|
Direct |
13,500
+50.0%
|
-
|
|
Jun 27
2024
|
David Hallal |
BUY
Grant, award, or other acquisition
|
Direct |
13,500
+4.25%
|
-
|
|
Jun 27
2024
|
Srinivas Akkaraju |
BUY
Grant, award, or other acquisition
|
Direct |
13,500
+50.0%
|
-
|
|
Jun 17
2024
|
Caryn Parlavecchio CHRO |
SELL
Open market or private sale
|
Direct |
4,305
-2.73%
|
$34,440
$8.98 P/Share
|
|
Jun 17
2024
|
Mo Qatanani CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
2,315
-1.57%
|
$18,520
$8.98 P/Share
|
|
Jun 17
2024
|
Junlin Ho GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
4,695
-2.25%
|
$37,560
$8.98 P/Share
|
|
Jun 17
2024
|
Edward H Myles COO & CFO |
SELL
Open market or private sale
|
Direct |
9,458
-4.48%
|
$75,664
$8.98 P/Share
|
|
May 09
2024
|
Amir Nashat |
BUY
Other acquisition or disposition
|
Direct |
13,133
+12.71%
|
-
|
|
May 09
2024
|
Amir Nashat |
SELL
Other acquisition or disposition
|
Indirect |
598,533
-61.12%
|
-
|
|
May 09
2024
|
Amir Nashat |
BUY
Other acquisition or disposition
|
Indirect |
98,855
+39.33%
|
-
|
|
Apr 09
2024
|
Katie Peng |
BUY
Grant, award, or other acquisition
|
Direct |
26,825
+50.0%
|
-
|
|
Feb 16
2024
|
Edward H Myles COO & CFO |
SELL
Open market or private sale
|
Direct |
4,744
-2.2%
|
$71,160
$15.74 P/Share
|
|
Feb 16
2024
|
Mo Qatanani CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
2,512
-1.68%
|
$37,680
$15.74 P/Share
|
|
Feb 16
2024
|
Caryn Parlavecchio CHRO |
SELL
Open market or private sale
|
Direct |
3,751
-2.32%
|
$56,265
$15.74 P/Share
|
|
Feb 16
2024
|
Jay T. Backstrom CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
11,614
-3.19%
|
$174,210
$15.74 P/Share
|
|
Feb 16
2024
|
Junlin Ho GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
3,489
-1.64%
|
$52,335
$15.74 P/Share
|
|
Feb 12
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
72,855
+50.0%
|
-
|
|
Feb 12
2024
|
Jay T. Backstrom CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
214,285
+37.04%
|
-
|
|
Feb 12
2024
|
Caryn Parlavecchio CHRO |
BUY
Grant, award, or other acquisition
|
Direct |
47,145
+22.6%
|
-
|
|
Feb 12
2024
|
Mo Qatanani CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
70,715
+32.11%
|
-
|
|
Feb 12
2024
|
Tracey Sacco CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
49,285
+50.0%
|
-
|
|
Feb 12
2024
|
Junlin Ho GENERAL COUNSEL |
BUY
Grant, award, or other acquisition
|
Direct |
57,855
+21.42%
|
-
|
|
Feb 12
2024
|
Edward H Myles COO & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
53,570
+19.89%
|
-
|